激活P21激酶6:一个有前途的工具,用于预测小细胞肺癌的诊断和治疗反应

相关实验视频

Updated: Sep 14, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Simei Chen¹, Kexin Han², Yinyi Chen³

¹Department of Blood Transfusion, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.

|July 25, 2025

概括

P21激活激酶6 (PAK6) 显示为小细胞肺癌 (SCLC) 的生物标志物具有前途. 血清PAK6水平升高与SCLC患者的诊断,治疗反应和更差的预后有关.

科学领域:

在瘤学瘤学.
生物标志物发现发现
分子诊断学分子诊断

背景情况:

P21激活激酶6 (PAK6) 与瘤进展和化学抵抗有关.
作为小细胞肺癌 (SCLC) 的诊断和预后生物标志物,PAK6的作用需要全面评估.

研究的目的:

评估SCLC中血清PAK6水平的诊断有效性和预后意义.
为了将PAK6水平与SCLC患者的临床特征和治疗反应相关联.

主要方法:

在SCLC患者,非小细胞肺癌 (NSCLC) 患者,肺结节 (PN) 患者和健康对照者 (NC) 中使用ELISA测量血清PAK6度.
已确定的瘤标志物 (NSE,CEA,CA19-9,ProGRP) 的水平被量化. 收集了无进展生存 (PFS) 数据.

主要成果:

与其他组相比,SCLC患者的血清PAK6水平显著更高 (p < 0.01).
与CEA和CA19-9相比,PAK6,NSE和ProGRP的诊断性能更好 (AUC为0.892,0.834,0.935),比CEA和CA19-9的诊断性能更好.
较高的PAK6水平与较差的SCLC预后和较短的PFS相关 (HR=2.02,P=0.001).
治疗后PAK6,NSE和ProGRP水平显著下降,与CEA和CA19-9不同.

结论:

血清PAK6是用于SCLC诊断,治疗监测和预后的宝贵生物标志物.
PAK6可能成为小细胞肺癌的潜在治疗点.

关键词:

在 NSE NSE 里面.在PAK6中,PAK6是PAK6.在ProGRP中,我们使用了ProGRP.血清瘤标志物血清瘤标志物小细胞肺癌是一种小细胞肺癌.

更多相关视频

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...